Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Minoxidil is an effective and safe treatment for common hair loss when applied to the skin, but more research is needed for optimal use.

Both treatment combinations improved hair growth similarly and were safe.

In this study, the authors highlight the potential of intradermal microinjections of dutasteride as an adjunctive therapy for androgenetic alopecia, though they note that information on its effectiveness remains limited.

In this study, DPHC from the brown alga Ishige okamurae demonstrated potential to prevent androgenic alopecia by inhibiting hair loss and promoting hair growth through multiple cellular mechanisms.

This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.

In clinical studies, inhibiting androgen receptor expression using CosmeRNA ARI SAMiRNA micelles effectively treated androgenetic alopecia by significantly increasing hair growth, as reported in this research.

This review discusses the potential usefulness and safety profile of oral antiandrogens for treating frontal fibrosing alopecia, noting possible benefits but acknowledges that finasteride's efficacy remains uncertain.

In this study, researchers found that Derinat, a TRPCs inhibitor, reduced oxidative stress and prolonged the anagen phase of hair growth in mice, supporting its potential as a therapy for androgenetic alopecia by improving clinical outcomes and enhancing quality of life for those affected.

This study reported that a novel ionic liquid delivery system combining ferulic acid and finasteride enhanced the solubility, skin permeation, and effectiveness in promoting hair regrowth in androgenetic alopecia mice, suggesting an improved topical treatment approach.

This study observed that both finasteride and dutasteride significantly decreased dihydrotestosterone concentrations in hair, with dutasteride showing the greatest reduction.

This study found that 60% of men with mild to moderate androgenetic alopecia showed improvement after treatment with botanically derived 5AR inhibitors, suggesting these compounds may be effective, though larger trials are needed.

In this study, researchers developed a new topical atraric acid formulation, AA-TF#15, which showed a significantly higher drug penetration and increased hair regrowth in mice compared to minoxidil and finasteride treatments, suggesting its potential effectiveness for treating scalp androgenic alopecia.

3-tetrazolo steroidal analogs can strongly inhibit the enzyme linked to hair loss.

In this study, YK11 was found to promote osteoblast cell proliferation and differentiation through activation of non-genomic signaling pathways in mouse osteoblast cells.

This study found that a 1% Sandalore® solution reduced hair shedding and improved hair volume and anagen phase duration in women with telogen effluvium over 24 weeks, compared to placebo.

This study found that a botanical extract increased Bcl-2 levels and improved the anagen-to-telogen hair ratio in men with androgenetic alopecia, suggesting potential for managing chemotherapy-induced alopecia.

This review discusses the roles of androgens and androgen receptor in skin diseases like acne and hirsutism, and highlights the promise of antiandrogen drugs, reporting no new clinical findings.

This study found that aliphatic ester moieties in 16-formyl-17-methoxy dehydroepiandrosterone derivatives increased their potency as 5α-reductase type 2 inhibitors in vitro compared to finasteride.

A new compound may effectively inhibit the enzyme linked to BPH and hair loss.

This study synthesized and evaluated hydroxycinnamate derivatives for their ability to inhibit human SRD5A1, finding that three compounds showed significant inhibitory activity and low cytotoxicity. Compound 10a notably reduced SRD5A1 protein expression in cells, suggesting potential for nonsteroidal treatment of androgen-related conditions.

This review found that dutasteride is more effective than finasteride in increasing hair count and shaft thickness for androgenetic alopecia in men, with potential for reduced systemic side effects through mesotherapy, although further research is needed on long-term safety and dosage.

This study found that certain pyrazole derivatives may serve as effective 5α-reductase inhibitors with potential use in the treatment of androgenetic alopecia, based on molecular docking analyses.

This study evaluated novel steroids' potential as future hormonal therapies for neuroprotection in glucose disorders, but emphasized that further research is needed to optimize androgen antagonist use in the context of COVID-19 progression.

This study found that antisense oligonucleotides can significantly reduce androgen receptor expression in cultured human sebocytes and may offer new therapeutic possibilities for androgen-associated skin diseases.

In this study, researchers explored the use of a 2-deoxy-D-ribose sodium alginate hydrogel on mice with androgenic alopecia and found it resulted in similar hair regrowth to minoxidil, highlighting increased hair follicle density and angiogenesis.

In this study, compound glycyrrhizin promoted hair regrowth in a testosterone-induced alopecia mouse model and increased human hair dermal papilla cell proliferation, likely through activating the Wnt/β-catenin pathway.

This study found that androgenetic alopecia treatments, especially dutasteride, are associated with a small increased risk of adverse events like sexual dysfunction and dermatologic reactions.

This study found that local therapy with trichoriboside and trichosaccharide significantly increased cAMP levels in hair follicles of men with androgenic alopecia, with trichoriboside showing greater activity.

This systematic review discusses various topical, oral, injectable, and non-pharmacological treatments for androgenetic alopecia, examining both current and emerging therapeutic options in addressing this common form of hair loss.